Agios Pharmaceuticals, Inc.

AGIO05 Dec 2024
Healthcare
$58.55
+0.01 (+0.97%)
Lowest Today
$57.91
Highest Today
$62.15
Today’s Open
$58.55
Prev. Close
$58.88
52 Week High
$62.58
52 Week Low
$20.96
To Invest in Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Healthcare
AGIO05 Dec 2024
+0.01 (+0.97%)
1M
3M
6M
1Y
5Y
Low
$57.91
Day’s Range
High
$62.15
57.91
52 Week Low
$20.96
52-Week Range
52 Week High
$62.58
20.96
1 Day
-
1 Week
-0.02%
1 month return
+27.13%
3 month return
+34.77%
6 month return
+21.51%
1 Year return
+163.74%
3 Years return
+81.89%
5 Years return
+48.05%
10 Years return
-
Institutional Holdings
Farallon Capital Management, L.L.C.
9.93
Vanguard Group Inc
9.72
BlackRock Inc
8.52
BB Biotech AG Ord
6.55
Bellevue Group AG
6.55
T. Rowe Price Associates, Inc.
4.97
State Street Corp
4.09

Market Status

Fundamentals
Market Cap
3357.94 mln
PB Ratio
2.06
PE Ratio
5.05
Enterprise Value
2413.44 mln
Total Assets
937.12 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Organisation
Agios Pharmaceuticals, Inc.
Employees
383
Industry
Biotechnology
CEO
Mr. Brian M. Goff M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step